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Production of cysteinyl-dopamine during intravenous dopamine Dopamine is the most readily oxidized and in vitro the
therapy. most cytotoxic of the naturally occurring catecholamines.
Background. Oxidized dopamine rapidly forms thiol-conju- Concentrations of 1025 mol/L destroy a variety of cellsgates with 2SH groups on cysteine, glutathione, and proteins.
in culture [1–3]. Oxidation of dopamine produces a qui-We used cysteinyl-dopamine production as an index of thio-
none that reacts avidly with nucleophilic sulfhydryl (SH)ester production during intravenous dopamine treatment of
critically ill patients. groups on cysteine and glutathione to form the SH con-
Methods. Cysteinyl-dopamine and catecholamines were mea- jugates 5-S-glutathionyl-dopamine (GSH-DA) and 5-S-
sured by high-performance liquid chromatography with electro- cysteinyl-dopamine (CYS-DA) [4, 5]. Conjugation of do-chemical detection. The production of cysteinyl-dopamine by
pamine-quinone with 2SH occurs 1000-fold faster thanpurified human neutrophils was measured using dopamine
production of aminochrome by internal cyclization [6].(1 mmol/L) and cysteine (1 mmol/L) concentrations similar to
those found during dopamine treatment. To examine the im- Formation of covalent bonds between dopamine-qui-
pact of endotoxic shock on cysteinyl-dopamine production, none and nucleophilic 2SH groups on proteins may dis-
anesthetized rats were given dopamine (12 to 15 mg/kg/min
rupt protein structure and enzyme activity. In addition,intravenously) with or without endotoxin (50 mg/kg intrave-
the oxidation of CYS-DA produces a variety of neuro-nously).
Results. In vitro, neutrophils converted 26% of dopamine toxic products such as dihydrobenzothiazines and benzo-
to cysteinyl-dopamine (30 min at 378C). Activating neutrophils thiazines [7–9]. These substances are lethal when injected
with zymogen increased dopamine consumption from 26 to into the brains of mice [10].68%, but only 36% appeared as cysteinyl-dopamine. The re-
Conditions that produce cytotoxic dopamine thiol-mainder may have been oxidized to other cysteinyl derivatives.
conjugates may exist when dopamine is used to treatEndotoxin increased cysteinyl-dopamine in rat plasma from
2.5 nmol/L (range ,0.2 to 11) to 9.7 nmol/L (range ,0.3 to 31, patients with septic or cardiovascular shock. Intravenous
P 5 0.1). After four hours, with or without endotoxin, cysteinyl- dopamine infusion for hours to days raises plasma uncon-
dopamine was ,0.3 nmol/L in cerebrospinal fluid. In the plasma
jugated dopamine concentrations to the micromolarof eight patients receiving dopamine (6 to 20 mg/kg/min for 1
range. Free radicals generated by activated neutrophilsto 3 days), dopamine was 0.5 to 9.9 mmol/L, and cysteinyl-
dopamine was 48 to 1660 nmol/L. Cysteinyl-dopamine was 4.3 [11] or from reperfusion after ischemia [11–13] could
to 22.6% of dopamine and correlated with leukocyte count (r 2 5 increase dopamine oxidation and the production of do-
0.388, P 5 0.099). pamine thiol-conjugates. This hypothesis was tested by
Conclusions. A significant fraction of exogenously adminis-
measuring CYS-DA production in vitro after incubationtered dopamine reacts with 2SH groups of cysteine and proba-
of dopamine with activated neutrophils, by measuringbly also with 2SH groups on peptides and proteins. During brief
dopamine treatment of endotoxic shock in rats, neither dopa- CYS-DA and GSH-DA concentrations in rats after en-
mine nor cysteinyl-dopamine crossed the blood–brain barrier. dotoxin injection and subsequent dopamine infusion,
and by measuring plasma CYS-DA and GSH-DA con-
centrations in critically ill patients who were receiving
dopamine infusions.
Key words: cerebrospinal fluid, glutathione, cysteine, hypotension, METHODS
shock, endotoxin, neutrophils.
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and endotoxin lipopolysaccharide from Escherichia coli— from the alumina by the addition of 0.15 mol/L HClO4
in a phosphate mobile phase. To quantitate the total cate-serotype 055:B5—were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). Sodium acetate, sodium octane cholamines (free and conjugated), urine was adjusted to a
pH of ,2 with 6 mol/L HCl and hydrolyzed for 60 minutessulfonate, and ethylenediaminetetraacetic acid (EDTA)
were obtained from BDH Inc. (Toronto, Ontario, Can- at 958C before extraction. The detection and quantitation
of CYS-DA were satisfactory using both systems. Nor-ada). Citric acid was obtained from JT Baker Chemical
Co. (Phillipsburg, NJ, USA). Acetonitrile high-perfor- epinephrine and GSH-DA had virtually identical reten-
tion times when analyzed by the JCL6000 system (aboutmance liquid chromatography (HPLC) grade and sodium
phosphate were purchased from Caledonian Labora- 5 min), but the peaks were well separated using the
Millennium system (,6.5 and 40 min, respectively). Con-tories Ltd. (Georgetown, Ontario, Canada). Dibutyl-
amine was obtained form Aldrich Chemical Co. (Mil- sequently, CYS-DA and GSH-DA were identified in
biological samples by a comparison of retention timeswaukee, WI, USA).
on both HPLC systems and by co-chromatography with
Catecholamine and 5-S-cysteinyl dopamine analysis standards. Recovery of all catecholamines with the ex-
ception of dihydroxyphenyl acetate (DOPAC) was be-Catecholamine analysis was performed using HPLC
with electrochemical detection. To increase analytical tween 65 and 85% following alumina extraction. The
recovery of DOPAC was consistently approximatelyspecificity, two different HPLC systems were used, with
different detector voltages, mobile phase composition, 50%. Interassay coefficients of variation were dihydroxy-
phenylglycol (DHPG) 6.0%, DOPA 3.1%, NE 2.8%, Eand pH. The JCL6000 system (Jones Chromatography
USA Ltd., Lakeword, CO, USA) used a guard column 4.6%, DOPAC 8.5%, dopamine 7.2%, CYS-DA 3.3%,
and GSH-DA 2.8% (N 5 10). The detection limit of bothfilled with C18 pellicular packing (Alltech Associates,
Deerfield, IL, USA) and a 3 mm packing LC-18 Sup- CYS-DA and GSH-DA (assuming 1.0 mL of undiluted
specimen was processed) was 0.1 nmol/L. Linearity waselcosil 4.6 3 75 mm column (Supelco Canada Ltd.,
Oakville, Ontario, Canada). The mobile phase was confirmed up to 200 nmol/L. CYS-DA was stable to
hydrolysis, but 99% of GSH-DA was destroyed by the50 mmol/L sodium acetate, 22.4 mmol/L citric acid,
1.35 mmol/L EDTA, 3.75 mmol/L sodium octane sulfo- procedure; therefore, we were unable to measure con-
jugated GSH-DA. Both GSH-DA and CYS-DA werenate, 0.01% (wt/vol) dibutylamine, and 4.5% (vol/vol)
acetonitrile, adjusted to pH 4.3 to 4.4 with acetic acid, stable at acid pH (HClO4, pH 1.1) and room temperature.
Standard solutions of GSH-DA and CYS-DA werefiltered (4.5 mm), and degassed. The flow rate was 0.7 mL/
min at an operating pressure of 9.4 Mpa (1200 psi). The stored at 2708C in 2 mol/L HCl.
To produce 5-S-cysteinyl dopamine, dopamine-HClHPLC was connected to a Model 5100A coulometric
detector consisting of three coulometric cells in series (20 mg, 0.105 mmol) and l-cysteine (35 mg, 0.22 mmol)
were incubated with mushroom tyrosinase (10 mg, 10,000(ESA Inc., Bedford, MA, USA). The conditioning cell
was set at 0.15 V. Analytical cell electrodes I and II were units) in 50 mL of 0.5 mol/L phosphate buffer (pH 6.5)
[4]. After 60 minutes, a dopamine peak was no longerset at 0.2 and 20.38 V, respectively. Data analysis was
performed by a JCL6000 Chromatography Data System detectable by HPLC, and the enzymatic reaction was
stopped by adding 5 mL of 4 mol/L HClO4. CYS-DA(Jones Chromatography USA Ltd.) connected to elec-
trode II. was isolated by elution with 2 mol/L HCl from a Dowex-
50 W-X4 (200 to 400 mesh hydrogen form) column. AThe Millennium HPLC system used a Zorbax C18
column with an online filter. The mobile phase consisted dark purple residue with ultraviolet absorption maxima
at 255 and 292 nm was obtained. Nuclear magnetic reso-of 100 mmol/L sodium phosphate, 0.27 mmol/L EDTA,
0.92 mmol/L sodium octane sulfonate, and 3.0% (vol/vol) nance (NMR) spectral analysis confirmed that the com-
pound was CYS-DA. To produce 5-S-glutathionyl dopa-acetonitrile and was adjusted to pH 3.6 with phosphoric
acid and degassed. The flow rate was 1.0 mL/min at an mine, dopamine HCl (40 mg, 0.21 mmol) and glutathione
(700 mg, 2.28 mmol) were incubated with mushroomoperating pressure of 9.4 Mpa (1200 psi). The HPLC
was connected to a Model Coulochem II coulometric tyrosinase (10 mg, 10,000 U) in 25 mL of 0.1 mol/L
ammonium acetate buffer (pH 5.8) for five hours [5]. Adetector consisting of four coulometric cells in series
(ESA Inc.). The guard cell was set at 0.15 V. Electrodes brown substance was obtained was eluted with 2 mol/L
HCl from a Dowex column. UV maxima were at 255I, II, III, and IV were set at 0.0, 0.0, 0.20 and 20.38 V,
respectively. Data analysis was performed by a Millen- and 292 nm [4, 5], and NMR spectral analysis confirmed
that the compound was GSH-DA. S-(N-acetylcysteinyl)-nium 2020 chromatography manager (Waters Associates
Inc., Millford, MA, USA). dopamine was synthesized by electrolysis of dopamine
to produce dopamine-o-quinone followed by addition ofCatecholamines and their metabolites, including
CYS-DA and GSH-DA, were extracted from plasma N-acetyl cysteine [8]. The major product of this reaction
has been identified by Shen, Zhang, and Dryhurst as 5-S-and urine with alumina. Catecholamines were released
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(N-acetylcysteinyl)-dopamine [8]. The reaction mixture method of Huang et al [14]. The rats were then infused
was extracted with alumina and separated with HPLC. with dopamine (15 mg/kg/min) for four to five hours.
The major unidentified peak appeared midway between Four of the rats also received 50 mg of endotoxin at the
the dopamine and CYS-DA peaks on the Millennium beginning of the dopamine infusion. CSF was collected
system. during the final two hours of the infusion. An additional
six anesthetized rats were infused with dopamine for five
Incubation of 5-S-cysteinyldopamine with hours without the cisternal catheter, and three of these
activated neutrophils rats also received endotoxin. Urine was collected during
Activated neutrophils were prepared from citrated the fourth hour of the dopamine infusion. Samples were
blood obtained from human volunteers. All reagents immediately centrifuged, separated into 1 mL aliquots,
were sterile. Blood was centrifuged for 20 minutes at and stored at 2708C until analysis.
175 3 g, and the plasma was removed down to the buffy
coat. This plasma was layered onto a button of 90% Cysteinyldopamine in plasma from patients receiving
percoll and centrifuged at 1000 3 g to produce platelet- intravenous dopamine
poor plasma. After removal of the plasma, the remaining
After obtaining informed consent or surrogate in-
cells were resuspended with 5 mL of 6% dextran T-500
formed consent, heparinized blood samples (7 mL) werein 0.9% wt/vol saline, made up to 50 mL with saline, and
collected from eight critically ill patients who were re-allowed to stand for 30 minutes. The supernatant was
ceiving intravenous dopamine (6 to 20.5 mg/kg/min) atthen centrifuged at 112 3 g for six minutes at room
the Toronto General Hospital Division of the Universitytemperature. The resulting pellet was resuspended in
Health Network. The samples were centrifuged immedi-2 mL of platelet-poor plasma and underlayered with 51
ately at 48C and stored at 2708C until analysis. Thisand 42% percoll gradients. The cells and percoll were
study was approved by the UHN Research Ethics Board.centrifuged at 180 3 g for 10 minutes, and then the
neutrophil-enriched intermediate layer was washed in
StatisticsHank’s solution containing 110 U/L heparin. The cells
Data were calculated using SigmaStat for Windowswere used immediately for further experiments; 107 neu-
(Jandel Scientific Software, San Rafael, CA, USA). Atrophils were incubated in 1 mL of Hank’s solution with
comparison of catecholamine results between the groups1 mol/L cysteine and 1 mmol/L dopamine with or without
was assessed by Kruskal–Wallis one-way analysis of vari-opsinized zymogen (25 mL) to activate them. These con-
centrations of cysteine and dopamine are typically en- ance (ANOVA) on ranks, followed by the Student New-
countered in the plasma of septicemic patients undergo- man–Keuls multiple comparison procedure to isolate the
ing dopamine therapy. After 30 minutes at 378C, the groups or groups that differed from the others. Statistical
reaction was stopped with 40 mL of 70% HClO4. Cate- significance was considered at P values of #0.5.
cholamines were measured in the supernatant after alu-
mina extraction. All assays were performed in triplicate.
RESULTS
Dopamine infusion into endotoxin-shocked rats Incubation of 5-S-cysteinyldopamine with
Male Wistar rats (310 to 350 g) were used to test the activated neutrophils
effect of endotoxic shock on the production of GSH- In the absence of neutrophils, 26 nmol/L (2.6%) of
DA and CYS-DA during dopamine infusion. Twenty- dopamine were converted to CYS-DA (Fig. 1). The addi-
four animals were anesthetized (50 mg/kg pentobarbitol tion of neutrophils to the incubation mixture increased
IP), catheterized, and infused for 60 minutes with 0.9%
the conversion of dopamine to CYS-DA by 10-fold to
wt/vol saline (3 mL/hour). Systolic blood pressure was
255 nmol/L (26% of initial dopamine concentration).monitored continuously through a cannula in the carotid
After neutrophil activation by zymogen, 680 nmol/L ofartery during the study. Groups 1 and 2 were given an IV
dopamine disappeared; however, the CYS-DA concen-bolus injection of Escherichia coli endotoxin—serotype
tration only increased to 364 nmol/L (36% of initial do-055:B5 (50 mg/kg body weight)—in 500 mL saline.
pamine concentration). Therefore, in an environment ofGroups 2 and 4 were given saline. After five minutes,
increased free radical production, the disappearance ofgroups 1 and 3 were infused with dopamine (12 mg/kg/
dopamine substantially exceeded the measured appear-min) for 30 minutes. Groups 2 and 4 were infused with
ance of CYS-DA. Apart from dopamine and CYS-DA,saline. Blood (6 mL) was then taken for catecholamine
no other metabolites were detected, except a minor un-measurement. Another group of eight rats was anesthe-
identified peak that was possibly a CYS-DA oxidationtized with inactin (100 mg/kg, IP) and prepared for col-
product. This peak was also observed in the CYS-DAlection of cerebrospinal fluid (CSF). A catheter was im-
planted in each rat’s cisterna magna following the standard.
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nephrine above that seen with endotoxin or dopamine
alone. CYS-DA was undetectable in plasma of rats that
did not receive dopamine. GSH-DA was not detected in
any of the plasma samples. Similar results were obtained
after five hours of dopamine infusion (Table 2). At that
time, plasma dopamine levels were lower, but the differ-
ence was not significant.
An unknown peak with the same retention time as
the major product from the reaction of dopamine-o-
quinone with N-acetylcysteine [8] appeared in chromato-
graphs of plasma from rats that received dopamine. The
unknown peak was not found in urine or in plasma from
control rats that did not receive dopamine. The peak
height was similar to that of CYS-DA. In rats that re-
ceived dopamine, endotoxin did not alter the mean peak
height of the unknown substance (67 6 31 mV after 30Fig. 1. Conversion of dopamine to 5-S-cysteinyl dopamine (CYS-DA;
min dopamine and 76 6 50 mV after dopamine plusj) by activated neutrophils. Dopamine (DA; 1 mmol/L, ) was incu-
bated with cysteine (Cys 1 mmol/L) for 30 minutes alone or in the endotoxin). After four to five hours, the peak heights
presence of 107 neutrophils (WBC)/mL. Zymogen was added to activate were 160 6 115 and 85 6 63 mV. In samples collected
the neutrophils. Neutrophils significantly increased CYS-DA produc-
after 30 minutes of dopamine infusion, the unknowntion and disappearance of dopamine (P 5 0.03, ANOVA). Activating
the WBC with zymogen increased dopamine removal (P 5 0.03) but peak tended to be inversely correlated with the CYS-DA
did not significantly increase CYS-DA production (N 5 3). peak (P 5 0.06 in the group that received endotoxin and
P 5 0.14 in the group that received dopamine without
endotoxin). There was no correlation of the unknown
peak with CYS-DA dopamine in the plasma collectedDopamine infusion into endotoxin-shocked rats
after four to five hours of infusion.
Systolic blood pressure was between 100 and 145 Urine excretion decreased to virtually zero for the first
mm Hg during the one-hour stabilization period prior hour following the injection of endotoxin; therefore, we
to endotoxin or saline injection. During the 10 minutes only examined the results for rats that received four to
following endotoxin injection, blood pressure decreased five hours of dopamine infusion. In preliminary studies
to 30% of baseline values in rats that received dopamine with dopamine infused rats, we found that urine free
and those that did not. Blood pressure increased over CYS-DA was 23 6 10% of total CYS-DA. Urine volume
the next 20 minutes to approximately 60% of baseline was too small to measure total as well as free CYS-DA
values and remained there for up to 4.5 hours. Blood in the endotoxin-treated rats. Endotoxin increased the
pressure did not alter significantly from baseline in the excretion of norepinephrine and epinephrine during do-
groups that received saline or dopamine without endo- pamine infusion (Table 3), but did not significantly alter
toxin throughout the experiment. Hematocrit levels in- the excretion of dopamine or CYS-DA. Urinary-free
creased significantly (P , 0.001) in rats that received CYS-DA excretion did not correlate with plasma dopa-
endotoxin but did not change in the others. mine or CYS-DA, but was correlated with plasma nor-
Intravenous dopamine, by itself within 30 minutes, epinephrine (P 5 0.02) and epinephrine (P 5 0.007) in
raised plasma concentrations of dopamine and CYS-DA the group that received both endotoxin and dopamine.
as well as the metabolites, DHPG and DOPAC (Table 1). Cerebrospinal fluid was collected during the final two
Endotoxin, by itself, increased DHPG, DOPA, norepi- hours of four- to five-hour dopamine infusions (Table 4).
nephrine, epinephrine, and DOPAC, but not CYS-DA CYS-DA was below the level of detection in all samples.
concentration. CYS-DA concentrations were not nor- Endotoxin did not increase the CSF concentrations of
mally distributed in rats that received dopamine alone. dopamine or its metabolites.
High CYS-DA concentrations were associated with tran-
Catecholamine analysis of plasma from patientssient incomplete anesthesia in two rats that did not re-
receiving intravenous dopamineceive endotoxin. The superimposition of intravenous do-
pamine on endotoxic shock increased plasma CYS-DA, Using both HPLC systems, CYS-DA was identified in
but because of the wide scatter of results the median plasma from eight patients that were receiving dopamine
concentration (9.7 nmol/L), was not significantly higher for a variety of acute critical conditions (Table 5). The
than with dopamine alone (2.3 nmol/L, P 5 0.13, Mann– CYS-DA concentration was related to plasma dopamine
Whitney rank sum test). The combination of endotoxin concentration (r2 5 0.97). Plasma CYS-DA as a percent-
age of dopamine tended to increase with white blood celland dopamine increased the concentration of norepi-
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Table 1. Plasma catecholamines metabolites after 30 minutes of dopamine infusion with and without endotoxin
Group DHPG DOPA E NE DOPAC DA CYS-DA
1 Endotoxin 18ab 5.1a 27ac 4.6abc 291ab 330ab 9.7ab
Dopamine (14–21) (4–6) (3–40) (3–7) (228–364) (200–389) (0.2–14)
2 Endotoxin 11a 7.0ac 24ac 2.3a 10a 2 ,0.4
Saline (11–16) (6–10) (9–39) (2–9) (6–15) (1–8)
3 Control 12a 7a 0.9a 2.1 242ab 282ab 2.3ab
Dopamine (11–14) (4–9) (0.7–0.9) (1–3) (124–349) (165–392) (0–2.6)
4 Control 6 2.0 ,0.2 1.7 4 0.2 ,0.3
(5.6–6.4) (2–9) (1–2) (3–5) (0.1–6)
Median concentration is in nmol/L with 25 to 75% confidence limits. Abbreviations are: DHPG, dihydroxy phenylglycol; DOPA, dihydoxyphenylalanine; E,
epinephrine; NE, norepinephrine; DA, dopamine; CYS-DA, 5-S-cysteinyl-dopamine. Endotoxin (50 mg/kg) was injected into groups 1 and 2, while groups 1 and 3
received dopamine (12–15 mg/kg·min IV). Blood was collected after 30 minutes of dopamine infusion with or without endotoxin or saline control. One-way ANOVA
on ranks P , 0.05. N 5 5 to 9 in each group.
a Significantly greater than group 4 (P , 0.05)
b Significantly greater than group 2 (P , 0.05)
c Significantly greater than group 3 (P , 0.05)
Table 2. Plasma catecholamines metabolites after 300 minutes of dopamine infusion with and without endotoxin
DHPG DOPA E NE DOPAC DA CYS-DA
Endotoxin 20a 4 48 14b 259 80 5
Dopamine (17–22) (4–6) (6–55) (10–16) (183–324) (53–179) (1.5–16)
Control 15 2 6 3 257 131 2.6
Dopamine (12–16) (1–4) (0.3–39) (1–4) (191–381) (62–427) (0–7.8)
Median concentration is in nmol/L with 25 to 75% confidence limits. Abbreviations are: DHPG, dihydroxy phenylglycol; DOPA, dihydoxyphenylalanine; E,
epinephrine; NE, norepinephrine; DA, dopamine; CYS-DA, 5-S-cysteinyl-dopamine. Endotoxin (50 mg/kg) was injected into one group (N 5 7) and the other group
received only saline (N 5 6). Both groups received dopamine (15 mg/kg/min IV). Blood was collected after 300 minutes of dopamine infusion with or without
endotoxin or saline control. P values are for an unpaired t test with DHPG and NE. Other metabolites were not significantly different.
a P 5 0.02, b P 5 0.03
Table 3. Effect of endotoxin on urine catecholamine excretion during the fourth hour of dopamine infusion
DHPG NE E DOPAC DA CYS-DA
Endotoxin
Dopamine 1162 2864a 4169b 22406400 33606550 9.563
Control
Dopamine 1361 13 63 663 15906350 30306800 4.562
Mean 6 SE excretion rates pmol/min. Dopamine was infused at 15 mg/kg/min into 5 rats. Urine was collected during the fourth hour of dopamine infusion, another
7 rats received dopamine plus endotoxin 50 mg/kg. P values are for an unpaired t test. Abbreviations are in the Table 2 legend.
a P 5 0.03, b P 5 0.02
Table 4. Catecholamine metabolites in cerebrospinal collected during dopamine infusion with and without endotoxin
DHPG DOPA NE DOPAC DA CYS-DA
Endotoxin
Dopamine 2161 1.260.2 2.561 152631 765 ,0.2
Control
Dopamine 1862 1.660.2 2.160.7 106626 461 ,0.3
Data are means 6 SE; concentration is in nmol/L. Dopamine was infused at 15 mg/kg/min into 4 rats. Another 4 rats received dopamine plus endotoxin 50 mg/kg.
Cerebrospinal fluid (CSF) was collected during the second to fourth hour of dopamine infusion from both groups.
(WBC) count (P 5 0.099; Fig. 2). Using stepwise forward fied peak appeared midway between dopamine and
CYS-DA in the patient’s plasma. This unknown peakregression analysis, the equation relating %CYS-DA/
dopamine to WBCs was not significantly improved by add- that may have been an N-acetyl cysteinyl-dopamine con-
jugate was smaller than the CYS-DA peaks.ing plasma dopamine, dopamine dose, duration of treat-
ment, or arterial pO2. There was no significant relationship In theory, dopamine should react with GSH as well as
with cysteine. An explanation for the absence of GSH-DAwith the nature of the primary diagnosis. GSH-DA was
not detected in any of the plasma samples. An unidenti- from the rat and human samples was sought by adding
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Table 5. 5-S-cysteinyl dopamine in plasma of patients receiving intravenous dopamine
Plasma Plasma
Age/sex DA dosea Other WBC 3 PO2 DA CYS-DA
years Condition lg/kg·min Days vasoactive drugs 109/L mm Hg lmol/L nmol/L
60/M Resp. arrest 8.6 3 13.9 106 0.5 113
51/M Resp. arrest 11.2 1 9.1 86 0.9 124
Lung transplant
74/M Myocardial infarct 17.5 1 Levophed 8.2 103 2.4 150
nitroglycerine
59/M GI bleed alcoholic liver disease 6 3 11.1 72 0.7 78
68/M Pancreatic abscess intra-abdominal bleed 6.7 2 Levophed 12.2 90 0.7 72
67/F Resp. failure, lung resection for CA 15.6 1 11.5 119 1.4 60
82/M Ruptured aortic aneurysm 8.5 1 8.1 115 0.9 48
48/F Double lung transplant 20.5 1.5 Epinephrine, levophed, 19.1 86 9.9 1,660
vasopressin
a Dopamine infusion at the time of sample collection
Table 6. Effect of g-glutamyl transpeptidase (GT) in human plasma
on conversion of 5-S-glutathionyl dopamine (GSH-DA) to
5-S-cysteinyl dopamine (CYS-DA)
High gGT plasma
High gGT plasma 1 acivicin
Minutes GSH-DA CYS-DA GSH-DA CYS-DA
0 860 ,0.15 860 ,0.15
5 356 43 818 6
30 117 108 807 16
Low gGT plasma
Low gGT plasma 1 acivicin
0 860 ,0.15 860 ,0.15
5 656 ,0.15 554 ,0.15
30 390 ,0.15 392 ,0.15
Concentration is in nmol/L. Glutathionyl-dopamine (GSH-DA) was added
to pooled plasma with high (270 U/L) or low (10 U/L) g-glutamyl transpeptidase
activity. Acivicin (1.5 mg/mL) was added to a paired sample to inhibit g-glutamyl
transpeptidase activity.
GSH-DA to pooled human plasma with high g-glutamyl
transpeptidase (g-GT) activity (279 U/L). GSH dopa-
mine (initially 860 nmol/L of plasma) was rapidly degraded
and more than 80% disappeared after 30 minutes of
incubation. The CYS-DA concentration increased from
,0.15 nmol/L to 108 nmol/L after 30 minutes. Preincu-
bation of the pooled plasma with acivicin to block g-GT
activity slowed the degradation of GSH-DA and CYS-DA
production so that after 30 minutes, 808 nmol/L of
GSH-DA remained and CYS-DA had only increased to
16 nmol/L (Table 6). Plasma with a low g-GT concentra-
tion did not produce CYS-DA, although GSH-DA disap-
peared. In this plasma, the removal of GSH-DA was not
sensitive to inhibition by acivicin.
Fig. 2. Unconjugated 5-S-cysteinyl dopamine (CYS-DA) expressed as DISCUSSION
a percentage of unconjugated dopamine (DA) in the plasma of patients
Dopamine is readily oxidized to an o-quinone by neu-undergoing dopamine treatment for acute illness. The percentage of
CYS-DA/DA relative to the leukocyte count (WBC; A) is 7.6 1 0.36 3 trophils in the presence of oxygen at physiological pH
WBC, and relative to the duration of dopamine treatment (days; B) is [15]. The highly reactive dopamine-quinone follows three%CYS-DA/DA 5 3.9 1 4.4 3 days, r 5 0.38. The lines indicate the
regression equation and 95% confidence limits. paths. It may (1) form conjugates with nucleophilic groups
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such as the 2SH on cysteine or proteins, (2) undergo of the plasma-free dopamine concentration. That neutro-
phils promote dopamine conjugation with cysteine isintramolecular cyclization, or (3) be reduced back to
the original catechol with the production of free oxygen suggested by the correlation between the percentage of
CYS-DA/dopamine and WBC count (P 5 0.099; Fig. 2).radicals [1, 6, 16]. Dopamine-quinone is 1000 times more
likely to react with nucleophilic 2SH groups if they are CYS-DA is only one product of many created by dopa-
mine–quinone interaction with 2SH groups [7–10, 18].available than to undergo intramolecular cyclization to
produce an indoline [6]. The neutrophil experiments The presence of conjugated CYS-DA in rat urine sug-
gests that an additional pool of conjugated CYS-DA wasdemonstrated the avidity of dopamine for 2SH groups
(Fig. 1). Neutrophils rapidly converted 26% of dopamine present in both rat and human plasma. Up to 70% of
oxidized dopamine may bind to protein 2SH groupsto CYS-DA when dopamine and cysteine concentrations
were similar to those that exist in critically ill patients [19]. Thus, we conclude that the free CYS-DA represents
only a small portion of the total DA-SH conjugatesduring treatment with dopamine (Table 5). Neutrophil
activation doubled the rate of dopamine disappearance formed by nucleophilic attack on oxidized dopamine in
these patients.with a 10% increase in CYS-DA production. The small
increase in CYS-DA is to be expected because CYS-DA During dopamine therapy, plasma dopamine concen-
trations are frequently greater than 1 mmol/L (Table 5),is more easily oxidized than dopamine. Oxidized CYS-DA
is converted to a variety of thiol-conjugates and their which is 1% of the LD50 for some cells in culture [20].
These concentrations of dopamine can alter proteinacetylated conjugates [7, 8, 10, 16].
The production of CYS-DA in anesthetized rats was structure and inactivate enzymes such as DNA polymer-
ase [21] and other 2SH dependent proteins [22]. Oxida-measured after dopamine infusion for 30 to 300 minutes.
At both 30 and 300 minutes, the unconjugated CYS-DA tion of CYS-DA produces dihydoxybenzothiazine, which
is lethal when injected into the mouse brain [16]. Cystei-concentration was approximately 1% of the plasma do-
pamine concentration (Tables 1 and 2). After three to nyl-DOPAC, derived from the reaction of cysteine with
oxidized DOPAC, is highly toxic to cultured P19 cellsfive hours of dopamine infusions, there was no detectable
CYS-DA in CSF and CSF dopamine concentration was and to hippocampal pyramidal neurons [9]. It is interest-
ing to note that DOPAC concentrations increased 50-less than 10% of plasma concentration (Table 4). Conju-
gated CYS-DA was not measured in plasma but was fold during the 30-minute dopamine infusion following
endotoxin injection (Table 1); however, we did not lookfound to be 23% of total CYS-DA in urine after acid
hydrolysis. Dopamine-quinone reacts avidly with gluta- for cysteinyl-DOPAC specifically.
The concentration of CYS-DA may be viewed in twothione as well as with cysteine [6]; however, no GSH-DA
was found in plasma or urine. The absence of GSH-DA ways: as an index of dopamine–quinone interaction with
2SH groups in general and as a reflection of the protec-is consistent with its rapid conversion to CYS-DA by
g-glutamyl transpeptidase (Table 6) [17] and to acetyl- tive effect of cysteine and glutathione. Glutathione and
cysteine, by forming thiol-conjugates with dopamine, re-ated thiol-conjugates by cysteine conjugate acetyl trans-
ferase [8]. duce the binding of dopamine to protein 2SH groups
[23]. This protective action is shown by reduced dopa-Endotoxemia did not significantly increase the conver-
sion of infused dopamine to CYS-DA in plasma or urine. mine-induced apoptosis in cultured PC12 cells [24]. How-
ever, while glutathione may reduce the reaction of dopa-Interpretation of these experiments is confounded by
sustained hypotension, which would have impaired renal mine with protein-SH groups, it does not necessarily
protect against the cellular disruption produced by highmetabolism and clearance of dopamine. Furthermore,
oxidative destruction of both dopamine and CYS-DA concentrations of dopamine [23], and as previously
noted, a number of the byproducts of GSH-DA andmay have increased as it did in the neutrophil experi-
ments (Fig. 1) [16]. Variable degrees of oxidative stress CYS-DA may be cytotoxic [7–10, 18].
We conclude that thioester formation contributes sig-could contribute to the wide range of plasma CYS-DA
concentrations and the consequent lack of a significant nificantly to the metabolism of dopamine during dopa-
mine therapy. Factors that promote oxidation of dopa-difference between the control and endotoxin treated
rats. Endotoxemia did not significantly increase the con- mine such as activated neutrophils will increase the
formation of dopamine-thiol-conjugates. The literaturecentration of dopamine or CYS-DA in CSF, which sug-
gests that at least for brief dopamine infusions with an indicates that some of the oxidized derivatives of
CYS-DA that are produced have toxic effects on theintact blood–brain barrier, the risk of central nervous sys-
tem exposure to dopamine and its conjugates is not great. brain. However, we found no evidence of CYS-DA in
the CSF during intravenous infusion of dopamine forCYS-DA appeared in the plasma (Table 5) and urine
(not shown) of critically ill patients undergoing treat- several hours in endotoxemic rats. The extent to which
the oxidized derivatives of CYS-DA are toxic outsidement with dopamine. Concentrations of free CYS-DA
were in the mmol/L range and ranged from 4 to 22.6% the brain is not known. One clinical report suggests that
Magnay et al: Cysteinyl-dopamine and thioester1898
9. Montine TJ, Picklo MJ, Amarnath V, et al: Neurotoxicity ofovert toxic effects are not seen in the short term following
endogenous cysteinylcatechols. Exp Neurol 148:26–33, 1997
treatment with high doses of dopamine. Two people 10. Shen XM, Dryhurst G: Further insights into the influence of
l-cysteine on the oxidation chemistry of dopamine: Reaction path-were reported to have left hospital neurologically normal
ways of potential relevance to Parkinson’s disease. Chem Res Tox-after receiving 33 to 25 mg/kg/min dopamine for three
icol 9:751–763, 1996
to seven hours for treatment of cardiac arrest [25]. We 11. Goode HF, Webster NR: Free radicals and antioxidants in sepsis.
Crit Care Med 21:1770–1776, 1993were unable to find any studies that examined the long-
12. Haglund U, Gerdin B: Oxygen free radicals and circulatory shock.term neurological or systemic consequences of dopamine
Circ Shock 34:405–411, 1991
treatment. 13. Kilgore KS, Lucchesi BR: Reperfusion injury after myocardial
infarction: The role of free radicals and the inflammatory response.
Clin Biochem 26:359–370, 1993ACKNOWLEDGMENT
14. Huang Y-L, Saljo A, Suneson A, Hansson H-A: A new approach
for multiple sampling of cisternal cerebrospinal fluid in rodentsThis work was supported by the Kidney Foundation of Canada.
with minimal trauma and inflammation. J Neurosci Methods 63:13–
22, 1995Reprints requests to Dr. Andrew D. Baines, Room 408, Banting Insti-
tute, 100 College Street, Toronto, M5G 1L5, Ontario, Canada. 15. Matthews SB, Henderson AH, Campbell AK: The adreno-
chrome pathway: The major route for adrenaline catabolism byE-mail: andrew.baines@utoronto.ca
polymorphonuclear leukocytes. J Mol Cell Cardiol 17:339–348,
1985
REFERENCES 16. Zhang F, Dryhurst G: Effects of l-cysteine on the oxidation
chemistry of dopamine: New reaction pathways of potential rele-1. Graham DG, Tiffany SM, Bell WR Jr, Gutnecht WF: Autoxida-
vance to idiopathic Parkinson’s disease. J Med Chem 37:1084–1098,tion versus covalent binding of quinones as the mechanism of
1994toxicity of dopamine, 6-hydoxydopamine, and related compounds
17. Burch PT, Aman M, Burch JW: Modification of glutathione con-toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644–
tent in platelet concentrates by the use of acivicin. Transfusion653, 1978
34:421–426, 19942. Michel PP, Hefti F: Toxicity of 6-hydroxydopamine and dopamine
18. Shen XM, Dryhurst G: Oxidation chemistry of (2)-norepineph-for dopaminergic neurons in culture. J Neurosci Res 26:428–435,
rine in the presence of L-cysteine. J Med Chem 39:2018–2029, 19961990
19. Scheulen M, Wollenberg P, Bolt HM, et al: Irreversible binding3. Giunta S, Galeazzi L, Groppa G: An in vitro bacterial model of
of DOPA and dopamine metabolites to protein by rat liver micro-cytotoxicity to living cells caused by dopamine and 6-hydroxydopa-
somes. Biochem Biophys Res Commun 66:1396–1400, 1975mine oxidation at physiological pH. Free Radic Biol Med 10:297–
20. Gabby M, Tauber M, Porat S, Simantov R: Selective role of303, 1991
glutathione in protecting human neuronal cells from dopamine-4. Rosengren E, Linder-Eliasson E, Carlsson A: Detection of 5-S-
induced apoptosis. Neuropharmacology 35:571–578, 1996cysteinyldopamine in human brain. J Neural Trans 63:247–253,
21. Monks TJ, Lau SS: Toxicology of quinone thioethers. Crit Rev1985
Toxicol 22:243–270, 19925. Ploemen JH, Van Ommen B, De Haan A, et al: Inhibition of
22. Bindoli A, Rigobello MP, Deeble DJ: Biochemical and toxico-human glutathione S-transferase by dopamine, alpha-methyldopa
logical properties of the oxidation products of catecholamines. Freeand their 5-S-glutathionyl conjugates. Chem Biol Interact 90:87–99,
Radic Biol Med 13:391–405, 19921994
23. Hastings TG, Lewis DA, Zigmond MJ: Role of oxidation in the6. Tse DCS, McCreery RL, Adams RN: Potential oxidative pathways
neurotoxic effects of intrastriatal dopamine injections. Proc Natlof brain catecholamines. J Med Chem 19:37–40, 1976
Acad Sci USA 93:1956–1961, 19967. Shen XM, Zhang F, Dryhurst G: Oxidation of dopamine in the
24. Offen D, Ziv I, Sternin H, et al: Prevention of dopamine-inducedpresence of cysteine: Characterization of new toxic products. Chem
cell death by thiol antioxidants: Possible implications for treatmentRes Toxicol 10:147–155, 1997
of Parkinson’s disease. Exp Neurol 141:32–39, 19968. Shen XM, Xia B, Wrona MZ, Dryhurst G: Synthesis, redox prop-
25. Olsen KH, Kluger J, Fieldman A: Combination high dose amri-erties, in vivo formation, and neurobehavioral effects of N-acetyl-
none and dopamine in the management of moribund cardiogeniccysteinyl conjugates of dopamine: Possible metabolites of rele-
shock after open heart surgery. Chest 94:503–506, 1988vance to Parkinson’s disease. Chem Res Toxicol 9:1117–1126, 1996
